16th week of 2015 patent applcation highlights part 34 |
Patent application number | Title | Published |
20150104395 | System and Method for Diagnosis of Astrocytic Brain Tumor - Methods and systems for distinguishing an astrocytic human brain rumor from a non-astrocytic human brain tumor (FIG. | 2015-04-16 |
20150104396 | METHOD FOR DETECTING CANCER USING ICG FLUORESCENCE METHOD - A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion. | 2015-04-16 |
20150104397 | AEROSOL DEVICE BASED ON A CALCIUM SALT AND A FIXING POLYMER - The invention relates to an aerosol device containing a cosmetic composition comprising: (i) from 0.1% to 15% by weight relative to the total weight of the composition, of one or more water-insoluble calcium salts, (ii) one or more fixing polymers, (iii) one or more C | 2015-04-16 |
20150104398 | TASTE MODULATOR AND METHOD OF USE THEREOF - The present invention is directed to a novel taste-masking composition comprising a taste-masking effective amount of an | 2015-04-16 |
20150104399 | PREVENTION OF FIBROBLAST COLLAPSE - The present technology is directed to extracts of plants of genus | 2015-04-16 |
20150104400 | TOPICAL DELIVERY AND ADMINISTRATION SYSTEM FOR STABILIZED PROTECTION AGENT, COMPOSITIONS AND METHODS OF MAKING SAME - The present invention provides a method and product for topical delivery and administration of stabilized protection agents and compositions thereof and methods for making the composition and use thereof. The method and system comprises pharmaceutical compositions for facilitating topical delivery of protection agents and skin anti-photoaging agents for inhibiting cellular degradation in response to sun damage. The pharmaceutical compositions are topically applied on a patient and are generally in a cream, lotion or gel form. | 2015-04-16 |
20150104401 | CATIONIC POLYGLYCERYL COMPOSITIONS AND COMPOUNDS - Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DP | 2015-04-16 |
20150104402 | CATIONIC POLYGLYCERYL COMPOSITIONS AND COMPOUNDS - Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DP | 2015-04-16 |
20150104403 | CATIONIC POLYGLYCERYL COMPOSITIONS AND COMPOUNDS - Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DP | 2015-04-16 |
20150104404 | POLYMER SYNERGY FOR IMPROVED HAIR STYLING - A hair styling composition comprises: 5 wt. % to 50 wt. % of a first nonionic polymer; 2 wt. % to 20 wt. % of a second nonionic polymer; and 2 wt. % to 15 wt. % of a cationic polymer. A method of making a hair styling composition comprises: combining 5 wt. % to 50 wt. % of a first nonionic polymer, 2 wt. % to 20 wt. % of a second nonionic polymer, and 2 wt. % to 15 wt. % of a cationic polymer to form a hair styling composition. | 2015-04-16 |
20150104405 | AQUEOUS COSMETIC PREPARATION - A method for producing an aqueous cosmetic composition containing the following components (A), (B) and (C):
| 2015-04-16 |
20150104406 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 2015-04-16 |
20150104407 | PROTEIN-POLYMER-DRUG CONJUGATES - A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described. | 2015-04-16 |
20150104408 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness. | 2015-04-16 |
20150104409 | HUMAN MONOCLONAL ANTIBODIES TO CTLA-4 - In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein. | 2015-04-16 |
20150104410 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules. | 2015-04-16 |
20150104411 | NOVEL ANTITUMORAL USE OF CABAZITAXEL - The invention relates to a compound of formula: | 2015-04-16 |
20150104412 | Materials and Methods Useful for Affecting Tumor Cell Growth, Migration and Invasion - It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein. | 2015-04-16 |
20150104413 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein. | 2015-04-16 |
20150104414 | CYTOKINES AND NEUROANTIGENS FOR TREATMENT OF IMMUNE DISORDERS - The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided. | 2015-04-16 |
20150104415 | Treatments of Hepatitis C virus infection - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection. | 2015-04-16 |
20150104416 | Leukemic Stem Cell Ablation - A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia. | 2015-04-16 |
20150104417 | COMPOSITIONS COMPRISING A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE - The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts. | 2015-04-16 |
20150104418 | BACTERIAL COMPOSITION - A bacterial composition that inhibits | 2015-04-16 |
20150104419 | FEEDLOT ADMINISTERED BACTERIAL COMPOSITION - A feedlot administered animal feed additive that promotes animal health and growth, reduces mortality and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and reduced pathogen sheading to the environment. The additive includes bacteria that inhibits | 2015-04-16 |
20150104420 | DAIRY ADMINISTERED BACTERIAL COMPOSITION - A dairy administered animal feed additive that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and reduced pathogen sheading to the environment. The additive includes bacteria that inhibits | 2015-04-16 |
20150104421 | CALF ADMINISTERED BACTERIAL COMPOSITION - A feed additive administered to juvenile animals such as calves that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and pathogen sheading. The additive includes bacteria that inhibits | 2015-04-16 |
20150104422 | FOS-BASED PREBIOTIC AND BACTERIAL-BASED PROBIOTIC - A composition including a pathogen inhibiting bacterial probiotic and a fructooligosaccharide (FOS) prebiotic particularly suited as a feed additive administered to juvenile animals such as calves that promotes animal health and growth, reduces scours and mortality, and can act as an antibiotic substitute. The additive inhibits pathogen growth resulting in lower pathogen load within the animal and pathogen sheading. The prebiotic-probiotic additive includes bacteria that inhibits | 2015-04-16 |
20150104423 | USE OF BLOOD GROUP STATUS III - The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 2015-04-16 |
20150104424 | Animal Health Improvement Composition and Method - Compositions and methods are provided for improving the health of an animal by reducing certain diseases and by binding certain heavy metals that may be unintentionally introduced into the body of the animal from the environment. Compositions and methods are also provided for improving the feed conversion ratio of an animal. In addition, compositions and methods are provided for reducing nitrate pollution in the environment. In one embodiment, the composition may include mastic gum, a mixture of ionic minerals, and optionally an essential amino acid not produced by the animal. The ionic minerals may be derived from water sourced from an inland sea such as the Great Salt Lake, the Dead Sea, or another inland sea. The essential amino acid may be included in the form of a protein. The animal may be a ruminant, poultry, or other animal. Methods are also provided for processing mastic gum. | 2015-04-16 |
20150104425 | Medical food for high cortisol breast cancer - A method of increasing effectiveness of breast cancer treatment or recovery using a medical food. This breast cancer medical food consists of transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations. The breast cancer medical food, administered correctly, reduces cortisol levels and enhances immune function. This method is applied to breast cancer patients with high cortisol levels. Dosage amounts are adjusted for client weight. Consumption frequency and dosage may be adjusted in response to cortisol measurements and killer T-cell-counts. Typically, consumption of the breast cancer medical food is done under professional supervision, and may be combined with other treatment strategies. | 2015-04-16 |
20150104426 | SKIN-CARE AGENT CONTAINING PLEUROTUS FERULAE FRUIT BODY EXTRACT OR PLEUROTUS FERULAE MYCELIUM EXTRACT - Disclosed is a composition for skin external application containing a | 2015-04-16 |
20150104427 | ENZYME-ASSISTED SPATIAL DECORATION OF BIOMATERIALS - A method of producing a hydrogel compromising a spatially-controlled, three-dimensional distribution of one or more bioactive signals is provided. The method compromises illuminating the hydrogel, wherein the hydrogel compromises a polymer bound to a peptide comprising a photolabile protected amino acid, wherein at least one portion of the hydrogel is illuminated to deprotect the protected amino acid, thereby converting the protected amino acid to a deprotected amino acid. Preferably, the deprotected amino acid is a substrate for an enzyme in at least one portion of the hydrogel. The method further comprises the step of contacting the hydrogel with the enzyme and a peptide comprising a bioactive signal, wherein the enzyme can form a bond between the substrate and the peptide comprising the bioactive signal, thereby producing a hydrogel compromising a plurality of bioactive signals occupying three dimensions of the hydrogel within at least one portion of the hydrogel subjected to illumination. | 2015-04-16 |
20150104428 | Compositions and Treatment Methods for Mesenchymal Stem Cell-Induced Immunoregulation - Mesenchymal Stem Cells (MSCs), including bone marrow-derived MSCs (BMMSCs) expressing Fas and FasL, and secreting MCP-1 are disclosed. Also disclosed are methods for upregulating regulatory T cells in a subject by administering MSCs, including BMMSCs. Also disclosed are methods for treating systemic sclerosis or colitis in a subject by administering MSCs, including BMMSCs. | 2015-04-16 |
20150104429 | SYNTHETIC TRITERPENOIDS AND METHODS FOR MODULATING STEM/PROGENITOR CELL GENE EXPRESSION - Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with an effective amount of a synthetic triterpenoid to induce the expression of one or more of SOX9 (Sex determining region Y-box 9), COL2A1 (Type II Collagen (alpha1)), TGF-βI, TGF-p2, TGF-33, BMP2, BMP4, BMPRII (Bone Morphogenic Protein Receptor II), SMAD (Small Mothers Against Decapentaplegic) 3, SMAD4, SMAD6, SMAD7, TIMP (Tissue Inhibitor of Metalloproteinase)-1 or TIMP-2 in the stem or progenitor cell, wherein the stem or progenitor cell is not a mesenchymal stem cell, periosteium cell or osteoprogenitor cell. In one embodiment, the stem or progenitor cell is multipotent. | 2015-04-16 |
20150104430 | Methods and Compositions for Generating Pancreatic Progenitors and Functional Beta Cells from hPSCs - Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component. | 2015-04-16 |
20150104431 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 2015-04-16 |
20150104432 | COMPLETE HUMAN SKIN ORGAN GENERATED FROM CULTURE-EXPANDED CELLS - Systems and methods can support generation of a full-thickness, human skin organ from tissue culture expanded cells. Human dermal and epidermal progenitor cells can be isolated from human tissues. Isolated cells may be cultured as epidermal cells while other isolated cells may be separately cultured as dermal cells. The cultured epidermal cells and dermal cells may be combined for co-culturing. The co-cultured cells may be suspended within a slurry. The co-cultured cells may be implanted onto a recipient organism for generation of a full-thickness skin organ comprising fully cycling hair follicles, adipose tissue, and other skin organ structures. | 2015-04-16 |
20150104433 | TAILORED RECOMBINASE FOR RECOMBINING ASYMMETRIC TARGET SITES IN A PLURALITY OF RETROVIRUS STRAINS - The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them. | 2015-04-16 |
20150104434 | ARTIFICIAL KIDNEY PRECURSOR AND PROCESS FOR PRODUCTION THEREOF - The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof. | 2015-04-16 |
20150104435 | METHODS AND COMPOSITIONS FOR PROVISION OF ANGIOGENIC FACTORS - Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; for provision of angiogenic factors to cells. In certain embodiments, provision of angiogenic factors to sites of neural degeneration stimulates growth and/or survival of host neurons. | 2015-04-16 |
20150104436 | APPLICATION AND PHARMACEUTICAL COMPOSITION OF PREACTIVATED AND DISAGGREGATED SHAPE-CHANGED PLATELETS - Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10 | 2015-04-16 |
20150104437 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES - The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a hone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis). | 2015-04-16 |
20150104438 | METHODS OF TREATING CANCER USING ANGIOGENIN OR AN ANGIOGENIN AGONIST - The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist. | 2015-04-16 |
20150104439 | PHARMACEUTICAL REMOVAL OF NEURONAL EXTENSIONS FROM A DEGENERATING DISC - The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically. | 2015-04-16 |
20150104440 | MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER - The current disclosure reveals a complex regulatory pattern between miR-31 and AR, indicating that miR-31 plays a key role in prostate cancer development and progression. Another aspect of the current disclosure shows that miR-31 directly targets and destabilizes AR mRNA through interaction with the AR mRNA coding sequence showing that miR-31, or a fragment thereof has the ability to act as a novel therapeutic agent in treating cancer. The current disclosure also shows that AR indirectly represses miR-31 expression by binding to the miR-31 promoter region and modulating methyltransferase activity. Another aspect of the current disclosure shows that miR-31 indirectly modulates AR activity by modulating regulators of cell cycle progression. The disclosure further provides an isolated nucleic acid that modulates the activity of the androgen receptor in a cell. The disclosure further provides a method of treating a prostate cancer in a subject, by administering to the subject an effective amount of an agent that modulates the activity or levels of miR-31. | 2015-04-16 |
20150104441 | IDENTIFICATION OF DISEASE-DRIVING ANTIGENS - Provided herein is technology relating to treating disease and particularly, but not exclusively, to methods for identifying disease-related antigens by assessing T cell receptor gene frequencies in diseased subjects. | 2015-04-16 |
20150104442 | PHOSPHOCOFILIN: COFILIN CO-LOCALIZATION INTENSITY AS A PREDICTOR OF METASTATIC RECURRENCE - Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided. | 2015-04-16 |
20150104443 | ANTI-ERBB2 ANTIBODY VARIANTS - The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with a low amount. | 2015-04-16 |
20150104444 | METHODS RELATED TO TRASTUZUMAB - The present invention relates to the characterization and production of trastuzumab. The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) trastuzumab. In some instances, methods herein allow highly resolved evaluation of trastuzumab useful for, inter alia, manufacturing trastuzumab, characterizing trastuzumab, identifying and/or confirming trastuzumab, monitoring the structure of trastuzumab, comparing trastuzumab preparations made over time or made under different conditions, and/or controlling the structure of trastuzumab. | 2015-04-16 |
20150104445 | METHODS OF INHIBITING THE ALTERNATIVE PATHWAY OF COMPLEMENT IMMUNE SYSTEM ACTIVATION AND COMPOSITIONS USED THEREIN - Methods and compositions are provided for treating diseases implicating alternative pathway complement immune system activation. | 2015-04-16 |
20150104446 | GENETIC AND ENVIRONMENTAL MARKERS TO IDENTIFY INFANTS AT RISK FOR SEVERE LUNG DISEASE - Provided herein are methods and compositions for determining the susceptibility of infants to severe respiratory syncytial virus (RSV) infections. Also provide are methods of treating said subjects prophylactically to reduce the incidence of such infections. | 2015-04-16 |
20150104447 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING BENRALIZUMAB - Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof. | 2015-04-16 |
20150104448 | Anti-Complement C1s Antibodies and Uses Thereof - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions. | 2015-04-16 |
20150104449 | Variant Immunoglobulins with Improved Manufacturability - This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels. | 2015-04-16 |
20150104450 | CTLA-4 Variants - Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life. | 2015-04-16 |
20150104451 | CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES - A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept. | 2015-04-16 |
20150104452 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2015-04-16 |
20150104453 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 2015-04-16 |
20150104454 | ANTI-C.DIFFICILE TOXIN ANTIBODIES AND ASSOCIATED METHODS - Embodiments of the invention are directed to a composition comprising a recombinant protein in soluble form wherein said recombinant protein comprises a portion of the | 2015-04-16 |
20150104455 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING ACUTE MYOCARDIAL INFARCTION - Compositions and methods for treating and diagnosing acute myocardial infarction are described. The invention also provides a method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or a combination of an antibody BMP-1-3 and an antibody to BMP-1-4 prior to AMI. | 2015-04-16 |
20150104456 | ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES - The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases. | 2015-04-16 |
20150104457 | IL-17 ANTAGONIST ANTIBODIES - The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases. | 2015-04-16 |
20150104458 | HOUSE DUST MITE ALLERGEN - A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1. | 2015-04-16 |
20150104459 | Compositions and Methods for the Therapy and Diagnosis of Influenza - The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides. | 2015-04-16 |
20150104460 | Human Antibodies and Specific Binding Sequences Thereof for use in Stroke and Ischemia or Ischemic Conditions - Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein. | 2015-04-16 |
20150104461 | ANTI-NOTCH2 NRR ANTIBODIES - The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same. | 2015-04-16 |
20150104462 | Use of Semaphorin-4D Binding Molecules for Treatment of Atherosclerosis - Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to Semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor. | 2015-04-16 |
20150104463 | METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT - The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject. | 2015-04-16 |
20150104464 | MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER - The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer. | 2015-04-16 |
20150104465 | IL-19 AS A BIOMARKER OF TSLP TREATMENT - The present invention relates to the use of IL-19 as a biomarker of treatment with a TSLP antagonist. | 2015-04-16 |
20150104466 | CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES - The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell. | 2015-04-16 |
20150104467 | MODULATION OF LEUKOCYTE ACTIVITY IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE - Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells into the brain, by reducing motility of neutrophil/myeloid cells in the parenchyma, by blocking Aβ-induced activation and adhesion of neutrophil/myeloid cells, and/or by blocking Aβ-induced integrin activation, degranulation and/or ROS release in neutrophil/myeloid cells. | 2015-04-16 |
20150104468 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY - The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates. | 2015-04-16 |
20150104469 | CARRIERS FOR IMPROVED DRUG DELIVERY - The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties. | 2015-04-16 |
20150104470 | IMMUNE MODULATION BY PERI-LYMPHATIC OR INTRA-LYMPHATIC CELL THERAPY - Disclosed are compositions of matter, methods of treatment, and protocols useful for therapeutic immune modulation using cell therapy administered perilymphatically or intralymphatically. In one particular embodiment, the invention provides means of treating an autoimmune condition by perilymphatic administration of a mesenchymal stem cell population. Said mesenchymal stem cell populations may be derived from umbilical cord tissues such as the Wharton's Jelly, amniotic membranes, or amniotic stem cells. In another particular embodiment Sertoli cells may be utilized as immune modulatory cells for the practice of the invention. | 2015-04-16 |
20150104471 | UNIVERSAL DONOR-DERIVED TOLEROGENIC CELLS FOR INDUCING NON-SYNGENEIC TRANSPLANTATION TOLERANCE - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject | 2015-04-16 |
20150104472 | C1q PEPTIDES AND USES THEREOF - Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X | 2015-04-16 |
20150104473 | ADJUVANT COMPOUND - The invention is directed to a compound according to the formula [1] wherein R | 2015-04-16 |
20150104474 | Methods of Inhibiting Gonad Maturation - The present invention provides a method of inhibiting maturation of the gonads of a juvenile animal which comprises administering to said juvenile animal an immunologically active molecule (IAM) or a vector comprising nucleic acid encoding an immunologically active molecule, said IAM being specific for a target protein within the gonads and binding thereto or causing an immune response against that target protein, and thereby inhibiting maturation of the gonads, as well as molecules of use in such methods. | 2015-04-16 |
20150104475 | COMPOSITIONS AND METHODS RELATED TO VIRAL VACCINES - Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof. | 2015-04-16 |
20150104476 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2015-04-16 |
20150104477 | UBIQUITINYLATED PROTEINS - A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC. | 2015-04-16 |
20150104478 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR - The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue. | 2015-04-16 |
20150104479 | MENINGOCOCCUS SEROGROUP X CONJUGATE - The invention provides a conjugate of a | 2015-04-16 |
20150104480 | INCREASING VIRUS-LIKE PARTICLE YIELD IN PLANTS - A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a structural virus protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP. | 2015-04-16 |
20150104481 | WATER EXTRACT OF ANTRODIA CAMPHORATA FOR IMMUNOSTIMULATORY EFFECT AND PREPARATION METHOD THEREOF - A preparation method for a water extract of the fruiting body of | 2015-04-16 |
20150104482 | USE OF CPG OLIGONUCLEOTIDES CO-FORMULATED WITH AN ANTIBIOTIC TO ACCELERATE WOUND HEALING - Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (TLR7) ligand activity, 2) an immunostimulatory K-type CpG oligodeoxynucleotide (ODN) comprising an unmethylated CpG motif, 3) an antibiotic, and 4) a surfactant, wherein the composition is formulated for topical administration. Methods for accelerating wound healing are also provided. These methods include topically administering the disclosed compositions. The wound can be in the skin or in the eye. | 2015-04-16 |
20150104483 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1 and the like. | 2015-04-16 |
20150104484 | STORED STRAIN POLYELECTROLYTE COMPLEXES AND METHODS OF FORMING - The present disclosure is directed to articles comprising a polyelectrolyte complex which stores mechanical strain and methods of forming articles comprising a polyelectrolyte complex which stores mechanical strain. | 2015-04-16 |
20150104485 | COMPOUNDS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Compounds of general formula (I): R | 2015-04-16 |
20150104486 | WOUND DRESSING - A wound dressing comprising a mat of gel forming fibres comprising silver, the mat having an open structure reinforced with textile fibres or threads, or fibres or threads of limited absorbency for use in the treatment of wounds. | 2015-04-16 |
20150104487 | FORMULATION AND USE THEREOF - A formulation is claimed, which contains at least one protective substance that is active with respect to cellulose-containing materials, such as wood-containing building materials in the form of solid wood or wood-based materials, and at least one specific compound with dispersing properties. The dispersants are branched comb-shaped polymers with polyether side chains, naphthalene-sulfonate-formaldehyde condensation products, melamine-sulfonate-formaldehyde condensation products and phosphatized polycondensation products. The formulations according to the invention are suitable in particular as plant protection agents and wood preservatives and are preferably used in the form of suspensions for pressure treatment of the respective building materials. | 2015-04-16 |
20150104488 | COMPOSITE MATERIAL WITH A SUPPORTING MATERIAL AND AN ANTIMICROBIAL AGENT - The invention relates to a composite material with at least one supporting material and at least one antimicrobial agent from the group of metals and metal compounds. The composite material comprises at least one hydrophilizing agent which increases the wettability of the surface of the composite material with water in comparison to the wettability of the surface of the composite material without the addition of the hydrophilizing agent. The invention further relates to a method for producing a composite material. | 2015-04-16 |
20150104489 | THERAPEUTIC FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION - The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing | 2015-04-16 |
20150104490 | Growth-inhibited hydroxyapatite, process for its preparation and use - A growth-inhibited hydroxyapatite is contained in agglomerates of prestructured collagen templates, wherein the prestructured collagen templates are denatured or broken up so that fibrillogenesis of the prestructured collagen templates is inhibited. Epitactic hydroxyapatite crystallites with a crystallite size below a critical nucleus radius are formed on the prestructured collagen templates. | 2015-04-16 |
20150104491 | SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY - The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days. | 2015-04-16 |
20150104492 | Esculentin 1a Derivatives and Uses Thereof - The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides. | 2015-04-16 |
20150104493 | Dissolvable Strip for Treatment of Oral Thermal Burns - A consumable film adapted to adhere and to dissolve in the oral cavity that provides a local anesthetic and therapeutic agents for the treatment of oral burns or injuries. The film is designed to instantly release benzocaine, or other types of local anesthetic or therapeutic agent, upon adhesion to the affected areas of the mouth, and will continue to release sufficient quantities for pain relief and for healing over an extended period of time. | 2015-04-16 |
20150104494 | METHODS FOR REPAIR OF EAR CANAL TISSUE DEFECTS - Disclosed herein are methods of repairing ear canal tissue defects by administering non-basic fibroblast growth factor (FGF) to the ear canal tissue defect. Also disclosed are delivery devices to administer said non-basic FGF. | 2015-04-16 |